The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms

International Journal of Impotence Research

Volumn 25, Issue 5, 2013, Pages 188-193

  Dalaklioglu, S ^a   Ozbey, G ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

corpus cavernosum; relaxation; resveratrol

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; RESVERATROL; SILDENAFIL; TETRYLAMMONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; ENDOTHELIUM; ISOLATED ORGAN; MALE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC GMP; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STILBENES; SULFONES; VASODILATOR AGENTS;

EID: 84884288266     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2013.6     Document Type: Article

References (47)

1. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417-450.
2. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-403.
3. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-94.
4. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
5. Ayta IA, Mckinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56.
6. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590-1600.
7. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts maleaging study. J Urol 1994; 151: 54-61.
8. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453-459.
9. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3: 28-36.
10. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jais X et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26: 813-825.
11. Ku the A, Montorsi F, Andersson KE, Stief CG. Phosphodiesterase inhibitors for the treatment of erectile dysfunction. Curr Opin Investig Drugs 2002; 3: 1489-1495.
12. Shoji T, Akazome Y, Kanda T, Ikeda M. The toxicology and safety of apple polyphenol extract. Food Chem Toxicol 2004; 42: 959-967.
13. Nagasako-Akazome Y, Honma D, Tagashira M, Kanda T, Yasue M, Ohtake Y. Safety evaluation of polyphenols extracted from hop bracts. Food Chem Toxicol 2007; 45: 1383-1392.
14. Shen CL, Chyu MC, Pence BC, Yeh JK, Zhang Y, Felton CK et al. Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report. BMC Complement Altern Med 2010; 10: 76.
15. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-3319.
16. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-9011.
17. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53: 7-15.
18. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann NY Acad Sci 2011; 1215: 161-169.
19. Jager U, Nguyen-Duong H. Relaxant effect of trans-resveratrol on isolated porcine coronary arteries. Arzneimittelforschung 1999; 49: 207-211.
20. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006; 6: 36-47.
21. Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium dependent vasorelaxing activity of wine and other grape products. Am J Physiol 1993; 265: H774-H778.
22. Naderali EK, Smith SL, Doyle PJ, Williams G. The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats. Clin Sci 2001; 100: 55-60.
23. Novakovic A, Gojkovic-Bukarica L, Peric M, Nezic D, Djukanovic B, Markovic-Lipkovski J et al. The mecanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci 2006; 101: 85-90.
24. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996; 27: 363-366.
25. Naderali EK, Doyle JP, Williams G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci 2000; 98: 537-543.
26. Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 2005; 105: 209-215.
27. Calderone V, Martelli A, Testai L, Martinotti E, Breschi MC. Functional contribution of the endothelial component to the vasorelaxing effects of resveratrol and NS 1619, activators of the large-conductance calcium-activated potassium channels. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 73-80.
28. Shin S, Jeon JH, Park D, Jang MJ, Choi JH, Choi BH et al. trans-Resveratrol relaxes the corpus cavernosum ex vivo and enhances testosterone levels and sperm quality in vivo. Arch Pharm Res 2008; 3: 83-87.
29. Yousif MH, Benter IF. Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats. Vascul Pharmacol 2007; 47: 281-287.
30. Myung SC, Han JH, Song KK, Kang GH, Lee SY, Kim TH et al. The effects of interleukin-6 on the contraction and relaxation responses of the cavernous smooth muscle from rats. Eur J Pharmacol 2008; 589: 228-232.
31. El-Metwally MA, Sharabi FM, Daabees TT, Senbel AM, Mostafa T. Involvement of alpha-receptors and potassium channels in the mechanism of action of sildenafil citrate. Int J Impot Res 2007; 19: 551-557.
32. Takagi M, Mochida H, Noto T, Yano K, Inoue H, Ikeo T et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur J Pharmacol 2001; 411: 161-168.
33. André E, Malheiros A, Cechinel-Filho V, Yunes RA, Calixto JB. Role of nitric oxide and K+ channels in relaxation induced by polygodial in rabbit corpus cavernosum in vitro. J Cardiovasc Pharmacol 2003; 41: 300-306.
34. Luckhoff A, Busse R. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflugers Arch 1990; 416: 305-311.
35. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
36. Moreland RB, Kim N, Nehra A, Goldstein I, Traish A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res 2003; 15: 362-368.
37. Chen G, Suzuki H. Calcium-dependency of the endothelium-dependent hyperpolarization of vascular smooth muscle cells of the rabbit carotid artery. J Physiol 1990; 421: 521-534.
38. Nagao T, Vanhoutte PM. Endothelium-derived hyperpolarizing factor and endothelium- dependent relaxations. Am J Respir Cell Mol Biol 1993; 8: 1-6.
39. Malmsjo M, Edvinson L, Erlinge D. P2U-receptor mediated endothelium-dependent but nitric oxide independent vascular relaxation. Br J Pharmacol 1998; 123: 719-729.
40. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Thapsigargin- and cyclopiazonic acid-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Br J Pharmacol 1995; 115: 987-992.
41. Adeagbo AS, Triggle CR. Varying extracellular [K+]: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol 1993; 21: 423-429.
42. Novakovic A, Bukarica LG, Kanjuh V, Heinle H. Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol 2006; 99: 360-364.
43. Gojkovic-Bukarica L, Novakovic A, Kanjuh V, Bumbasirevic M, Lesic A, Heinle H. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J Pharmacol Sci 2008; 108: 124-130.
44. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs 2010; 15: 467-480.
45. Liu J, Chen J. [Ion channels and penile erection]. Zhonghua Nan Ke Xue 2004; 10: 403-406410.
46. Li HF, Tian ZF, Qiu XQ, Wu JX, Zhang P, Jia ZJ. A study of mechanisms involved in vasodilatation induced by resveratrol in isolated porcine coronary artery. Physiol Res 2006; 55: 365-372.
47. Martinez-Pineiro L, Galicia de PedroI, Cisneros J, Cuervo E, Frias Iniesta J, Martinez-Pineiro JA. New features of pharmacologic treatment of erectile dysfunction. Arch Esp Urol 1996; 49: 270-276.